Introduction
Treatment with statins is the cornerstone of primary and secondary cardiovascular disease prevention [1, 2] . Statins are generally well tolerated, but myopathic symptoms known as statin induced myopathy (SIM) may preclude their administration. The manifestations may vary from subjective symptoms such as muscle pain, weakness and cramps to increased plasma creatine kinase (CK) levels. The most serious adverse muscle side effect, rhabdomyolysis, however is very rare: 1 in 10,000 patient years [3] . So-called statin-associated muscle symptoms such as muscle pain, aching, stiffness, weakness or cramps are encountered more frequently (7%-29%), in many cases without significant increase in plasma CK levels [3, 4] . Although these symptoms are mostly not life threatening, they may lead to down-titration of the dose or discontinuation of statins in up to 75% of cases, which contributes to increased adverse cardiovascular outcomes [3, [5] [6] [7] .
Objective assessment of muscle side effects remains a challenge. Currently no unified recommendations to enhance accurate diagnosis and approve statin associated muscle symptoms or treatment approach are generally accepted. The common practice in case of suspicion of statin induced muscle side effects is to down-titrate the statin dose, switch to a different statin or discontinue the treatment [3] . Alternatively, etiopathogenic treatment of SIM can be considered. Statins are known to inhibit synthesis of several biologically active substances, including ubiquinone and dolichols, which have been related to SIM [8] . Supplementation with ubiquinone also known as coenzyme Q10 (CoQ10) has been used in clinical practice. However, there was no evidence of its efficacy in a meta-analysis of six trials including 302 patients and in a randomized trial with 120 patients [9, 10] .
Polyprenols are natural long-chain isoprenoid alcohols with chemical formula H-[CH 2 -C(CH 3 ) CH-CH 2 ] n -OH with n standing for the number of isoprene units. They are naturally present in conifer tree needles in small amounts and are known to be metabolized in human liver to dolichol which is an important bioregulator of N-glycoprotein synthesis [11] .
We therefore hypothesized that supplementation with polyprenols in combination with CoQ10 could reduce statin induced muscle symptoms and improve objective myopathy parameters.
2.
Material and methods
Study design and patients
This was an open-label, one-center prospective pilot study.
Between June 2014 and July 2015 patients at the Latvian Center of Cardiology were screened for suspected SIM symptoms. The study was approved by the local Committee of Ethics at the Paul Stradins Clinical Hospital (study protocol No. 160414 -3L) and performed according to good clinical practice. The inclusion criteria were as follows: (i) presence of at least one of symptoms associated with statin use (muscle pain or muscle weakness, or muscle cramps for at least 2 weeks, or elevated CK level >2Â and <10Â above the upper limit of reference (ULR); (ii) stable dose of a statin used for at least for 1 month; (iii) no indication to decrease statin dose (symptoms are tolerable and CK level <10Â above ULR); (iv) expected to continue the same statin in the same dose during study period (as lipid targets are achieved or muscle symptoms are likely to increase with increasing statin dose); (v) patient has signed informed consent for participation in the study.
Patients were excluded from the study if they met any of the following exclusion criteria: CK level >10Â ULR; muscle symptoms present before statin therapy; regular intramuscular injections; serious suspicion of other cause of muscle symptoms; myocardial infarction or extensive surgery, or major trauma during the last one month; any surgery during last 2 weeks (except of PCI); elective surgical procedure in next 2 months (except for PCI); concomitant use of fibrates, nicotinic acid, red yeast extract, grapefruit juice, macrolide antibiotics, oral antifungal drugs, HIV protease inhibitors, cyclosporine, oral glucocorticiods (if change in dosage expected in the following 2 months), fluoxetine (if change in dosage expected in the following 2 months); liver enzyme elevation (AlAT or AsAT >3Â ULR and/or conjugated or unconjugated bilirubin >2Â ULR, with exception for Gilbert's syndrome), glomerular filtration rate < 30 mL/min as calculated by Cockroft-Gault formula; hyperkalemia ≥5 mmol/L; excessive consumption of alcohol (>5 units daily); established neuromuscular pathology, rheumatic polymyalgia, mitochondrial myopathies; established clinically significant hypothyroidism with planned change in thyroxin dosage; known or suspected poor compliance; any disease associated with poor life expectancy; regular excessive physical exertions; drug abuse; inability to perform exercise test; pregnancy or a possibility of conception during the following next 2 months; known intolerance of polyprenols or CoQ10; and allergies to conifer trees.
All patients received supplementation with conifer-tree needle polyprenols (4 mg daily) and CoQ10 (100 mg daily) for 8 weeks in the form of two food supplements registered in Latvia: 2 capsules of ''Poliprenols'' ® (containing 1 mg of needletree polyprenols) and one capsule of ''Kardiopren'' ® (containing 100 mg of CoQ10 and 2 mg of conifer-tree polyprenols) [12, 13] .
Data collection
After the baseline visit, two follow-up visits were planned: at 4 weeks (AE7 days) and at 8 weeks (AE7 days 
Statistical analysis
Statistical analysis was performed with IBM # SPSS # (version 22.0). Quantitative variables were described as mean value and standard deviation with exception of variables with non-normal distribution in which case median and interquartile range is reported. Categorical variables were described by amount and percentage. When two independent groups were compared, t test for independent samples, Mann-Whitney U test, chi-square test and Fisher exact tests were used as appropriate. Repeated measures ANOVA was used to test significance of changes in quantitative variables during study period. In cases when assumption of sphericity was violated as estimated by Mauchly's test of sphericity, Greenhouse-Geisser correction was used. Sidak adjustment was used for pairwise comparisons. Quantitative variables with non-normal distributions were tested with non-parametric Friedman's test for repeated measures. Changes of binary variables in repeated measures were tested with Cochran's Q test. P values less than 0.05 were considered as statistically significant.
Results

Baseline characteristics
Of the 14 patients (7 men and 7 women) enrolled in the study, 11 completed it per protocol (Fig. 1) . Two patients withdrew informed consent during the study. One patient was not willing to undergo repeated electromyography scheduled at 8 weeks. Another patient was unable to attend 8 weeks follow-up due to work assignments abroad. The study agents were discontinued by an investigator in the third patient due to liver safety concerns, which is described separately (see below Safety). The baseline characteristics of per protocol group and three excluded patients are summarized and compared in Table 1 . Alkaline phosphatase levels were significantly lower in excluded group, and no other parameters were significantly different. Statin doses and muscle symptoms are given in Table 2 . The localization of the muscle symptoms in per protocol group was the following: hips/thighs (n = 7, 63.4%), calves (n = 7, 63.4%), upper arms (n = 4, 36.4%), lower arms (n = 2, 18.2%), lower back (n = 3, 27.3%), upper back and other locations were less prevalent (n < 3). None of patients received other lipid-lowering drugs. The mean duration of statin treatment at the current dose before inclusion in the study was 9.9 AE 11.6 months (range: 1-36 months) in the total sample. The corresponding treatment duration was 10.8 AE 12.9 months (range: 1-36 months) and 6.6 AE 5.2 (range: 2-12 months) in per protocol and excluded groups, respectively (P = 0.602). History of previous statin dose reduction due to muscle symptoms or CK elevations was reported by 7 patients (63.6%) and 3 patients (100%) in per protocol and excluded groups, respectively (P = 0.505). Five (45.5%) and one (33.3%) patients reported previous intolerance of other than currently used statin in respective groups. Five patients (45.5%) had a history of intolerance of at least one other statin. Majority of patients had established atherosclerotic cardiovascular disease (Table 1) . At the entry only 4 of the 14 patients (28.6%) had reached their therapeutic target of LDL-C below 1.8 mmol/L. The safety and efficacy findings are reported for per protocol group. The results of electromyography will be reported separately.
Safety
None of the patients in per protocol group (n = 11) experienced major adverse events during the 8 weeks. One patient underwent uncomplicated elective PCI during the study 114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142   143   144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162   163   164   165  166  167   168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198 between week 4 and 8. No statistically significant increase was observed in levels of studied biochemical, hematologic and ECG variables (Table 3 ). There was a statistically significant mild reduction of triglyceride levels (P = 0.023). Higher CK levels at 8 weeks were observed, but were not statistically significantly different from those at baseline and at 4 weeks (P = 0.765 and P = 0.718, respectively; Sidak adjustment for multiple comparisons). Three patients had CK levels >ULR at the baseline. At 4 and 8 weeks 5 and 4 patients had such elevations of CK, respectively (P = 0.223).
One patient (65-year-old female) was excluded from the study due to asymptomatic increase of liver enzymes at the 4-week follow-up visit. The summary of the relevant biochemical data is given in Table 4 . Considering liver enzyme elevations more than 3 times above ULR, the statin (20 mg atorvastatin used for 7 weeks before inclusion and continued at the same dose during the study) was also discontinued. After 1 week of follow-up rapid normalization of the biochemical parameters was observed (Table 4 ). Other possible hepatotoxic factors were excluded (negative foe viral hepatitis B and C, no structural changes in liver and biliary system on ultrasound, patient denied use of any other drugs or substances). These changes were not accompanied by any symptoms or increase in CK or bilirubins. Of note, the patient had chronic kidney disease with GFR 50 mL/min, mild subclinical hypothyroidism (TSH 4.2 mU/L with URL 4.0 mU/L), and mildly decreased 25-OH-vitamin D levels (21.81). The renal function, however, did not worsen.
Efficacy
Muscle symptoms
Gradual and significant self-reported improvement of muscle pain (n = 10) and weakness (n = 7) was observed during the follow-up over 8 weeks according to self-assessment symptom scores (P < 0.001 and P = 0.018, respectively; Fig. 2 
muscle pain there was a statistically significant improvement at weeks 4 and 8 compared to baseline (P = 0.010 and P = 0.001, respectively), but not at week 8 compared to week 4 (P = 0.070). Reduction of muscle cramp severity (n = 5) was not statistically significant across the study (P = 0.069), but differed at week 8 compared to baseline (adjusted P = 0.012, Fig. 2 ). Muscle pain completely disappeared in 2 patients (20%), and 4 patients (40%) observed the reduction of the muscle pain score by at least 50%. The score did not change in 1 patient and decreased by less than 50% in 3 patients. Muscle weakness completely resolved in 3 patients (42%), did not change in 2 patients (29%) and decreased by less than 50% in 2 patients (29%). Cramps disappeared in two patients (40%) and decreased by at least 50% in other two patients (40%), while did not change in one patient (20%).
Overall, among 11 patients completing the study only 2 patients did not have any improvements of any of their symptoms. At the end of the study, 4 (40%) of the 10 patients in whom there was an indication to use higher than previously maximal tolerated statin dose, assessed subjective symptoms as having improved enough to consider up-titration of statin dose. One (10%) of patients had such improvement at week 4.
Dynamometry, exercise test and physical activities
All patients reported right arm as the dominant. The maximal and average results of the three measurements for each arm did not change during the study (Table 5) . No changes in any parameters of exercise veloergometry test were observed. The self-reported mild physical activities increased during the study (33.27 AE 12.56, 35.82 AE 16.20 and 39.55 AE 18.93 hours per week at baseline, 4 and 8 weeks, respectively, P = 0.008, Fig. 3 ).
Discussion
To our knowledge this is the first pilot study evaluating safety and efficacy of polyprenols in combination with CoQ10 in patients with SIM symptoms. Although this combination appeared to be generally well tolerated and safe in the majority of patients, we observed significant, but asymptomatic and reversible elevations of liver enzymes in one case. The patient was female with GFR <60 mL/min and mild subclinical hypothyroidism, mild vitamin D deficiency and no compelling evidence of liver disease. It is impossible to conclude if any of these factors alone or in combination were predisposing the patient to this event. The role of the baseline statin treatment on liver enzyme elevations cannot be ruled out either. Nevertheless, for future studies we recommend to either avoid the combination of polyprenols and CoQ10 in patients with GFR <60 mL/min or monitor such patients closely if any of these factors are present. If polyprenols are used, for safety reasons we currently recommend to test liver enzymes and CK levels at 4 weeks routinely, and to consider these tests at 2 weeks in patients with GFR <60 mL/min and/or with elevated TSH. The role of vitamin D deficiency as a risk factor for   238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256   257  258  259   260  261  262  263  264  265  266  267   268   269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287 288 
FU, follow-up; AlAT, alanine amino transferase; AsAT, aspartate amino transferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; CK, creatine kinase; GFR, glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein.
m e d i c i n a x x x ( 2 0 1 6 ) x x x -x x x hepatotoxicity, however, seems less likely, as the mean 25-OHvitamine D level was low in most patients of per protocol group (24.17 AE 6.17 ng/mL), although higher than in the patient with elevated liver enzymes (21.81 ng/mL). Of note, only two out of 11 patients in per protocol group had normal vitamin D levels ≥30 ng/mL, an intriguing finding in the context of previous reports suggesting vitamin D deficiency as a risk factor of statin induced muscle symptoms [14] [15] [16] . Contrary to our expectations, we did not observe reduction of CK levels. Moreover, there appeared to be some increase of CK levels during 8 weeks, which was not significant, but clinical relevance cannot be ruled out. It should be noted that the distribution of CK in the study sample was negatively skewed and non-parametric Friedman's test for repeated measures was therefore applied. Thus small sample size in combination with lower power of the non-parametric tests leaves high probability of type 2 statistical error. Irrespectively, we recommend to closely monitor CK levels in future studies of polyprenols alone or in combination with CoQ10, especially in patients with CK levels in the range of 5-10 times above the ULR. Having said that, we found no evidence of worsened muscle symptoms in patients with increase of CK levels, and there was no correlation of CK changes with regression of muscle symptoms. Clearly, if confirmed, the significance and mechanisms of CK changes with polyprenols should be further investigated.
The study has several limitations. Our attempt to develop very stringent criteria to select ''true'' SIM patients lead to a small sample size, which limits the power of the study. These patients were selected at the Latvian Center of Cardiology, among thousands of patients during 18 months. The challenge was to find patients meeting inclusion criteria, and there were very few cases where patients could not be included because of the exclusion criteria. This reiterates previous observations that the true prevalence of statin induced myopathies is much lower than commonly perceived.
Another limitation was the fact that only 11 of the 14 patients completed the study. In investigators' opinion only one case of discontinuation, however, was likely related to the study supplements as discussed above. Two other patients withdrew from the study due to clearly personal reasons unrelated to the study and had no record of poor tolerability or non-compliance. Nevertheless, an attrition or observer bias cannot be ruled out. It should also be noted that the patient sample was rather heterogeneous. For instance, the statins and doses varied. We did not attempt to switch patients to a unified treatment as patients had various experiences with other statins and/or doses. This may be regarded also as a strength of the study, because every patient was receiving maximum tolerated dose of the statin, which was previously individually tailored. In terms of cardiovascular risk the sample was less heterogeneous as they all had established coronary heart disease, although not all had the history of myocardial infarction or revascularization.
The current study was designed before the publication of several important position papers on the statin intolerance [3, 4, 17] . We therefore did not calculate statin myalgia clinical index score recommended by the European Atherosclerosis Society and supported by the International Lipid Expert Panel [3, 4, 17] . In the future research of polyprenols this score should be used for selection and characterization of the patients at the study entry.
This was an open-label, non-controlled, single center study, and all the results should be therefore interpreted with caution. Thus, the placebo effect and potential observer bias cannot be ruled out. Nevertheless the clinical efficacy surpassed the expectations of the investigators and was appreciated by several patients. Seven of them expressed willingness to continue the study agents after the completion of the study, as they are available as food supplements. Importantly, 4 patients were ready to increase the dose of statin at the end of the study .   289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317   318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360 The results should be put into context of the fact that all patients received only combination of polyprenols and CoQ10, which does not allow distinguishing the effects of either of the two agents. The design of the study was planned before the publication of an important meta-analysis of randomized trials, which did not suggest any significant benefit of CoQ10 supplementation in improving statin-induced myopathy [9, 18] . Another systematic review and meta-analysis, however, demonstrated a significant reduction in plasma CoQ10 concentrations in patients treated with statins [19] . There is a rational therefore to further investigate role of CoQ10 in statin-induce myopathy, probably with higher doses [21] . When our study was designed there was evidence that patients with statin-induced myopathy would benefit from CoQ10 in two studies [21, 22] which was not confirmed in other studies [23] [24] [25] . Hence, this was planned as a pilot study to test if the combination is safe and if there is a signal of clinical efficacy. Based on the current findings there is a rational to perform randomized double-blind placebo controlled prospective parallel group study where monotherapy of polyprenols and combination of polyprenols with CoQ10 are tested against each other and placebo to clarify the role of polyprenols in alleviation of the statin induced muscle symptoms.
Conclusions
Conifer-tree polyprenols in combination with CoQ10 may be generally safe in patients with SIM, but caution should be exercised in patients with glomerular filtration rate <60 mL/ min and routine monitoring of the liver enzymes and CK is advocated in all patients. Significant improvement of SIM symptoms observed in this study provides the rationale for a larger, double-blind controlled study with polyprenols.
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